![](https://i.imgur.com/CLvY2jA.png")
The vaccines must be expanded for the new virus variant. Moderna and Biontech are again the favorites for the first approval. But who is actually ahead? And: Is it still worth investing billions in these vaccines?
Biontech was faster again. Last week, the Mainz-based company, together with its US partner Pfizer, announced that the first of 1,420 subjects had been vaccinated with an omicron-specific vaccine. A day later, competitor Moderna followed suit. The race for the Omicron Booster is in full swing. WELT explains which manufacturers have good chances - and which vaccines could be the next big breakthrough.
https://www.welt.de/wirtschaft/plus23669...oster.html
Biontech was faster again. Last week, the Mainz-based company, together with its US partner Pfizer, announced that the first of 1,420 subjects had been vaccinated with an omicron-specific vaccine. A day later, competitor Moderna followed suit. The race for the Omicron Booster is in full swing. WELT explains which manufacturers have good chances - and which vaccines could be the next big breakthrough.
https://www.welt.de/wirtschaft/plus23669...oster.html
